FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to use of an agent containing a functionally significant fragment of human apolipoprotein A-I as an agent for treating craniocerebral injury. Use of an agent comprising a functionally significant fragment of human apolipoprotein A-I (rApoA-I-3-243), having an amino acid sequence of human ApoA-I-1-243, truncated from N-end by 2 amino acid residues, identified as SEQ ID NO 1, as an agent for treating craniocerebral injury.
EFFECT: this application allows improving locomotor activity and cognitive functions, as well as reducing morphological disorders in the structure of brain tissues of the subject.
3 cl, 2 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING AND PREVENTING HYPERGLYCEMIA AND INSULIN RESISTANCE AND RELATED DISEASES AND FUNCTIONAL DISORDERS OF ORGANS AND SYSTEMS AND AGENT FOR ITS IMPLEMENTATION | 2023 |
|
RU2823334C1 |
| NEW APPLICATION | 2004 |
|
RU2416426C2 |
| ARTIFICIAL PEPTIDE FOR CRANIOCEREBRAL INJURY TREATMENT | 2023 |
|
RU2816919C1 |
| MEDICINAL AGENT SHOWING MULTIFACTOR NEUROPROTECTIVE AND NOOTROPIC EFFECT IN CRANIAL TRAUMA | 2005 |
|
RU2318501C2 |
| MEDICATION, PROVIDING NEURO-PROTECTIVE ACTION IN ACUTE PERIOD OF CRANIOCEREBRAL INJURY | 2009 |
|
RU2414901C2 |
| METHOD FOR TREATMENT OF CEREBROVASCULAR BRAIN DISORDERS (OPTIONS) | 2017 |
|
RU2659674C1 |
| MEDICINAL AGENT OFFERING ANTI-ISCHEMIC, ANTIHYPOXIC AND ANTICONVULSANT EFFECT IN CRANIAL TRAUMA | 2005 |
|
RU2309745C2 |
| MODIFIED PEPTIDE AND USING IT FOR CNS CANCER SCREENING AND THERAPEUTIC EFFECTIVENESS TESTS | 2009 |
|
RU2491291C2 |
| APPLICATION OF PTERIDINE DERIVATIVES FOR TREATMENT OF HIGH INTRACRANIAL PRESSURE, SECONDARY ISCHEMIA AND DISEASES ASSOCIATED WITH HIGHER CONTENT OF CYTOTOXIC AND REACTIVE OXYGEN COMPOUNDS | 2003 |
|
RU2348410C2 |
| METHOD FOR MODELING CRANIOCEREBRAL INJURY WITH PERSISTENT NEUROLOGICAL DEFICIENCY | 2020 |
|
RU2739700C1 |
